Chantal M Morel

Dr. Chantal M Morel

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2021 in BMJ Global Health
Verified
Journal Article
Open access
PDF file
DWDidier Wernli
Didier Wernli
MCMia Clausin
Mia Clausin
NANino Antulov-Fantulin
Nino Antulov-Fantulin
JBJohn Berezowski
John Berezowski
NBNikola Biller-Andorno
Nikola Biller-Andorno
OYOran Young
Oran Young
The current global systemic crisis reveals how globalised societies are unprepared to face a pandemic. Beyond the dramatic loss of human life, the COVID-19 pandemic has triggered widespread disturbances in health, social, economic, environmental and governance systems in many countries across the world. Resilience describes the capacities of natural and human systems to prevent, react to and recover from shocks. Societal resilience to the current COVID-19 pandemic relates to the ability of societies in maintaining their core functions while minimising the impact of the pandemic and other societal effects. Drawing on the emerging evidence about resilience in health, social, economic, environmental and governance systems, this paper delineates a multisystemic understanding of societal resilience to COVID-19. Such an understanding provides the foundation for an integrated approach to build societal resilience to current and future pandemics.

26 May 2021 in International Journal of Health Policy and Management
Verified
Journal Article
Open access
PDF file
DWDidier Wernli
Didier Wernli
FTFabrizio Tediosi
Fabrizio Tediosi
KBKarl Blanchet
Karl Blanchet
KLKelley Lee
Kelley Lee
CMChantal M Morel
Chantal M Morel
Oran R. YoungOran R. Young
Oran R. Young

7 July 2023 in BMJ Open
Verified
Journal Article
Open access
PDF file
MCMia Clausin
Mia Clausin
ARAlicia Rieckhoff
Alicia Rieckhoff
FTFabrizio Tediosi
Fabrizio Tediosi
CMChantal M Morel
Chantal M Morel
YKYuliya Kaspiarovich
Yuliya Kaspiarovich
DWDidier Wernli
Didier Wernli
Objectives Research on resilience to the COVID-19 pandemic has primarily focused on health system resilience. The purpose of this paper is to: (1) develop a broader understanding of societal resilience to shocks by evaluating resilience in three systems: health, economic and fundamental rights and freedoms and (2) to further operationalise resilience in terms of robustness, resistance and recovery. Settings 22 European countries were selected based on the availability of data in the health, fundamental rights and freedoms, and economic systems during the first wave of the COVID-19 pandemic in early 2020. Design This study uses time series data to assess resilience in health, fundamental rights and freedoms, and economic systems. An overall resilience was estimated, as well as three of its components: robustness, resistance and recovery. Results Six countries exhibited an outlier excess mortality peak compared with the prepandemic period (2015–2019). All countries experienced economic repercussions and implemented diverse measures affecting individual rights and freedoms. Three main groups of countries were identified: (1) high health and high or moderate economic and/or fundamental rights and freedoms resilience, (2) moderate health and fundamental rights and freedoms resilience and (3) low resilience in all three systems. Conclusions The classification of countries into three groups provides valuable insights into the multifaceted nature of multisystemic resilience during the first wave of the COVID-19 pandemic. Our study highlights the importance of considering both health and economic factors when assessing resilience to shocks, as well as the necessity of safeguarding individual rights and freedoms during times of crisis. Such insights can inform policy decisions and aid in the development of targeted strategies to enhance resilience in the face of future challenges.

30 May 2025 in Antibiotics
Verified
Journal Article
Open access
PDF file
EIEdna Ibrahim
Edna Ibrahim
CMCharity Mkwanda
Charity Mkwanda
Edward Bamus MasoambetaEdward Bamus Masoambeta
Edward Bamus Masoambeta
LSLuigia Scudeller
Luigia Scudeller
TKTomislav Kostyanev
Tomislav Kostyanev
CMChisomo Lawrence Msefula
Chisomo Lawrence Msefula
Background/Objectives: Wastewater treatment plants (WWTPs) serve as a sink for both antimicrobial residues and bacteria carrying resistant genes, which are later disseminated into the environment, facilitating the spread of antimicrobial resistance. This study investigated the presence of extended-spectrum beta-lactamase (ESBL) producing Escherichia coli (Ec), Klebsiella pneumoniae (Kp), and Enterobacter cloacae (Enc) in effluent from WWTP in Blantyre, Malawi, to generate evidence and provide baseline information for interventions. Methods: Selective chromogenic agar was used to identify ESBL-producing bacteria. Results: A total of 288 samples were collected between April 2023 and March 2024, and 97.6% (281/288) yielded one or more presumptive ESBL isolates. Bacterial growth was confirmed as 48.9% Ec (255/522), 33.0% Kp (172/522), and 10.0% Enc (52/522). Antibiotic susceptibility testing showed the highest resistance to ceftriaxone (Ec, 100.0%; Kp, 98.3%; Enc, 100.0%) and the lowest resistance to meropenem (Ec, 6.3%, Kp, 1.2%; Enc, 3.8%) among the antibiotics that were tested. Multiple antibiotic resistance phenotypes were observed in 73.1% of the isolates, with the most prevalent phenotype being amoxicillin + clavulanate/cotrimoxazole/doxycycline/ciprofloxacin/gentamicin/azithromycin/ceftriaxone (55, 15.7%). Conclusions: The study demonstrated ongoing environmental contamination with antibiotic-resistant bacteria from sewage effluent. Therefore, the functionality of WWTPs should be improved to minimize the release of these organisms into the environment.

26 March 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
EIEdna Ibrahim
Edna Ibrahim
CMCharity Trinity Mkwanda
Charity Trinity Mkwanda
Edward Bamus MasoambetaEdward Bamus Masoambeta
Edward Bamus Masoambeta
LSLuigia Scudeller
Luigia Scudeller
TKTomislav Kostyanev
Tomislav Kostyanev
CMChisomo Lawrence Msefula
Chisomo Lawrence Msefula
Background/Objectives: Wastewater treatment plants (WWTP) serve as a sink for both antimicrobial residues and bacteria carrying resistant genes which are later disseminated into the environment, facilitating the spread of antimicrobial resistance. This study investigated the presence of extended spectrum beta-lactamase (ESBL) producing Escherichia coli (Ec), Klebsiella pneumoniae (Kp) and Enterobacter cloacae (Enc) in effluent from WWTP in Blantyre, Malawi, to generate evidence and provide baseline information for interventions. Methods: Selective chromogenic agar was used to identify ESBL-producing bacteria. Results: A total of 288 samples were collected between April, 2023 and March, 2024 and 97.6% (281/288) yielded one or more presumptive ESBL isolates. Bacterial growth was confirmed as 48.9% Ec (255/522), 33.0% Kp (172/522) and 10.0% Enc (52/522). Antibiotic susceptibility testing showed higher resistance to ceftriaxone (Ec, 100.0%; Kp, 98.3%; Enc, 100.0%) and lower resistance to meropenem (Ec, 6.3%, Kp, 1.2%; Enc, 3.8%) among the antibiotics that were tested. Multiple antibiotic resistance phenotypes were observed in 73.1% of the isolates with the most prevalent phenotype as AUG-SXT-DXT-CIP-GM-ATH-CRO (55, 15.7%). Conclusions: The study demonstrated ongoing environmental contamination with antibiotic resistant bacteria from sewage effluent. Therefore, the functionality of WWTP should be improved to minimize the release of these organisms into the environment.

Verified
Journal Article
Open access
PDF file
Edward Bamus MasoambetaEdward Bamus Masoambeta
Edward Bamus Masoambeta
GNGanizani Nansongole
Ganizani Nansongole
LSLuigia Scudeller
Luigia Scudeller
TKTomislav Kostyanev
Tomislav Kostyanev
FLFinola Leonard
Finola Leonard
JCJobiba Chinkhumba
Jobiba Chinkhumba
Background: Antimicrobial resistance (AMR) poses a significant threat to global health and economic development. In Malawi, the economic costs associated with the treatment of AMR infections remain largely unknown which may hinder resource allocation and policy prioritization. Method: The study used a cross-sectional design and was conducted between September 2023 and January 2025 at three different hospital settings. Data were collected from inpatients with laboratory-confirmed urinary tract infection (UTI) or blood stream infection (BSI). Additional follow-up data were collected from patients for four weeks post discharge. We analyzed patient level data first using descriptive statistics and employed an instrumental variable 2-stage least squares regression to estimate drivers of AMR treatments costs. Results: A total of 610 patients participated in the study. Of these, 45% had AMR-associated resistant infections. Overall, E. coli (43%) followed by P. aeruginosa (22%), K. pneumoniae (14%), and S. aureus (10%) were the most common pathogens. UTI was marginally more common (51%) compared to BSI (49%). BSI had a higher average cost than UTI for patients with both susceptible and resistant infections. On average, a patient spent MK283,815.10 (US$163.71) ranging from zero to MK13,500,000 (US$7786.90). Patients with resistant infections incurred, on average, MK161,785 (US$93.32) more than patients with susceptible infections, largely driven by prolonged hospitalization among other factors. Overall, the direct medical observed costs averaged MK37,165.29 (US$21.44) while direct non-medical observed costs averaged MK61,908.71 (US$35.71). Productivity losses for the patient and guardian(s) were a major observed cost averaging MK160,322.80 (US$92.49). The regression results further showed that having a bank account as a proxy of wealth, non-farm business, longer travel duration, BSI, and K. pneumoniae as the causative pathogens were significantly associated with increased cost burden among the patients. Conclusions: AMR-associated infections impose substantial economic burden on patients and households. Further strengthening of AMR surveillance and stewardship are needed as critical elements of Malawi’s National Action Plan. However, measures should also be taken to mitigate the economic consequences related to AMR, especially for patients who bear the brunt of these costs for lack of financial protection in Malawi’s health system.